newsfilter
← Latest News
ACCESS Newswire·

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

  • Ascendiant Capital Markets issued an updated equity research report on IGC Pharma (NYSE: IGC) on June 9, 2026.
  • The firm raised its price target for IGC Pharma shares to $5.50.
  • The report identifies additional clinical data and progress in 2026 as potential strong catalysts for the stock.
  • IGC's lead program, IGC-AD1, is currently under evaluation in the Phase 2 CALMA clinical trial for agitation associated with Alzheimer's disease.
  • IGC Pharma leverages AI to develop therapeutics for Alzheimer's, metabolic disorders, amyloid plaques, tau proteins, and neurodegeneration.
  • The company is advancing the CALMA trial toward upcoming operational and clinical milestones.
  • Ascendiant Capital Markets states the report is titled "Reports Q1 2026. We believe more positive clinical data and progress in 2026 to be strong catalysts for stock. Raising P/T to $5.50."
  • IGC Pharma disclaims endorsement of the analyst report and assumes no obligation to update or correct its contents.
  • The press release includes forward-looking statements regarding trial enrollment, safety, efficacy, regulatory approvals, and data readout timing.